Point of Care Solution
Veralize’s patented technology uses state-of-the-art Graphene Carbon-Nanotubes that are mixed with two preserved regions of synthetic (single-stranded-DNA) COVID-19 genome.
The nanotubes are an excellent support matrix to present the single-stranded-DNA (ss-DNA) probe fragments for hybridization with the test sample’s ss-RNA.
Test sample’s virus shell (if present) from fresh saliva samples will be broken down by our patent-pending process, thus releasing the ss-RNA within the shell.
Positive test occurs when the test sample’s ss-RNA hybridizes with the probe’s ss-DNA strands, producing an increased electric charge.
GCN support matrix
Manufactured in the US to the highest standards, our Veralize test device sensitivity is comparable to the gold standard, RT-PCR, and has clinically shown 98% accuracy. Veralize provides test results in under 7 minutes.
The Veralize system is designed to identify a wide range of cancers and infectious diseases by encoding our proprietary nanotube sensors with appropriate genetic detection information.
COVID-19 testing will not disappear. As COVID-19 morphs from a transient pandemic to a permanent endemic, physicians and patients will continue to want to know that their flu-like symptoms do not mean COVID. Patients and their doctors will want a specific diagnosis.
Our saliva test offers consumers a POC alternative to lab tests (accurate, but slow and expensive) and antigen tests (cheap and fast, but 40% accurate).
Veralize offers doctors & patients a quick, accurate POC test, similar to common quick strep tests. LOI from health system for ambulatory sites.
Rapid, accurate, POC tests are needed for inpatient surgeries (LOI) and outpatient surgeries.